Aerpio Pharmaceuticals, Inc. (ARPO)
(Delayed Data from NSDQ)
$1.04 USD
+0.01 (0.96%)
Updated May 3, 2019 04:13 PM ET
After-Market: $1.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.04 USD
+0.01 (0.96%)
Updated May 3, 2019 04:13 PM ET
After-Market: $1.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
QIAGEN's (QGEN) NeuMoDx Multiplex Test Receives FDA EUA
by Zacks Equity Research
QIAGEN's (QGEN) new NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test strengthens the company's portfolio in PCR testing, while becoming a crucial diagnostic tool for the flu season and the pandemic.
Aerpio Pharmaceuticals (ARPO) Is in Oversold Territory: What's Next?
by Zacks Equity Research
Aerpio Pharmaceuticals (ARPO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
What Makes Aerpio Pharmaceuticals, Inc. (ARPO) a New Buy Stock
by Zacks Equity Research
Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aerpio (ARPO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Aerpio (ARPO) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.
Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study
by Zacks Equity Research
Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA filing.
Horizon (HZNP) Provides Preliminary 2020 Financial Results
by Zacks Equity Research
Horizon (HZNP) provides 2020 preliminary financial results and updates on its key drugs.
Ultragenyx (RARE) Presents Preliminary 2020 Revenues & Guidance
by Zacks Equity Research
Ultragenyx (RARE) provides preliminary 2020 Crysvita revenues and 2021 revenue guidance for the same.
Aerpio Pharmaceuticals (ARPO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Aerpio Pharmaceuticals (ARPO) has been struggling lately, but the selling pressure may be coming to an end soon.
Aerpio (ARPO) Seeks Strategic Options for Pipeline Programs
by Zacks Equity Research
Aerpio (ARPO) unveils strategic alternatives after it announced top-line results from a phase II study of razuprotafib in glaucoma patients in December.
Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress
by Zacks Equity Research
Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.
Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis
by Zacks Equity Research
Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.
Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU
by Zacks Equity Research
Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.
Apellis' (APLS) Pipeline Candidate Pegcetacoplan Promising
by Zacks Equity Research
Apellis' (APLS) lead pipeline candidate, pegcetacoplan, is a promising one and being developed for several indications.
Bristol Myers' (BMY) CNS Phase III Cancer Study on Opdivo Fails
by Zacks Equity Research
Bristol Myers' (BMY) phase III study on Opdivo in newly diagnosed glioblastoma failed to meet goals.
Roche's (RHHBY) Phesgo Gets EU Nod to Treat Breast Cancer
by Zacks Equity Research
Roche's (RHHBY) fixed-dose combination of Perjeta and Herceptin administered subcutaneously gets approved by the EC for the treatment of early and metastatic HER2-positive breast cancer.
Jazz (JAZZ) Initiates BLA Submission for Leukemia Candidate
by Zacks Equity Research
Jazz (JAZZ) initiates the submission of a BLA to the FDA for the marketing approval of JZP-458 for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.
ChemoCentryx (CCXI) Reports Positive Top-Line Rare Disease Data
by Zacks Equity Research
ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma report positive top-line data from the study evaluating avacopan for the treatment of C3 Glomerulopathy.
Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU
by Zacks Equity Research
Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.
Ultragenyx (RARE), Mereo Ink Deal for Bone Disease Candidate
by Zacks Equity Research
Ultragenyx (RARE) and Mereo BioPharma ink an agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.
Novartis (NVS) to Acquire Neuroscience Company for Up to $770M
by Zacks Equity Research
Novartis (NVS) to buy neuroscience company, Cadent, for up to $770 million.
Novartis' (NVS) Entresto Gets FDA Panel Nod for Expanded Use
by Zacks Equity Research
Novartis (NVS) gets positive review from the FDA Advisory Committee to support the use of Entresto in the treatment of patients with heart failure with preserved ejection fraction.
Sangamo Therapeutics (SGMO) Catches Eye: Stock Jumps 6.5%
by Zacks Equity Research
Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Roche (RHHBY) Gets FDA Nod for Shorter Infusion Time of Ocrevus
by Zacks Equity Research
The FDA approves Roche's (RHHBY) Ocrevus for two-hour infusion time, dosed twice-yearly to patients with relapsing or primary progressive MS.
Seagen (SGEN) Gets Positive CHMP Opinion for Breast Cancer Drug
by Zacks Equity Research
Seagen (SGEN) gets a positive opinion from the CHMP, recommending the approval of Tukysa for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer.
Bristol Myers (BMY) Gets Positive CHMP Opinion for Inrebic
by Zacks Equity Research
Bristol Myers (BMY) gets positive CHMP opinion for Inrebic for the treatment of adult patients with newly diagnosed and previously treated myelofibrosis.